Deutsche Bank AG set a $175.00 target price on Illumina, Inc. (NASDAQ:ILMN) in a report published on Friday morning. The brokerage currently has a hold rating on the life sciences company’s stock.

ILMN has been the topic of a number of other reports. Zacks Investment Research raised shares of Illumina from a hold rating to a buy rating and set a $195.00 price objective on the stock in a report on Thursday, July 27th. Vetr raised shares of Illumina from a buy rating to a strong-buy rating and set a $196.75 price objective on the stock in a report on Monday, April 24th. Canaccord Genuity reissued a hold rating and set a $170.00 price objective on shares of Illumina in a report on Wednesday, July 26th. Barclays PLC reissued a hold rating and set a $150.00 price objective on shares of Illumina in a report on Wednesday, July 19th. Finally, BidaskClub lowered shares of Illumina from a sell rating to a strong sell rating in a report on Tuesday, July 25th. Four research analysts have rated the stock with a sell rating, eight have given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of Hold and a consensus price target of $167.02.

Illumina (NASDAQ ILMN) traded down 1.00% during trading on Friday, hitting $172.12. The stock had a trading volume of 243,333 shares. Illumina has a 12 month low of $119.37 and a 12 month high of $189.48. The stock has a market cap of $25.13 billion, a price-to-earnings ratio of 34.84 and a beta of 0.84. The firm has a 50 day moving average of $174.64 and a 200-day moving average of $171.82.

TRADEMARK VIOLATION NOTICE: This news story was posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.watchlistnews.com/illumina-inc-nasdaqilmn-pt-set-at-175-00-by-deutsche-bank-ag/1465635.html.

In other Illumina news, SVP Charles Dadswell sold 1,609 shares of the company’s stock in a transaction dated Wednesday, May 3rd. The shares were sold at an average price of $187.07, for a total value of $300,995.63. Following the completion of the transaction, the senior vice president now owns 10,936 shares in the company, valued at $2,045,797.52. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Jay T. Flatley sold 15,000 shares of the company’s stock in a transaction dated Tuesday, July 18th. The stock was sold at an average price of $170.77, for a total transaction of $2,561,550.00. Following the completion of the transaction, the director now owns 534,176 shares of the company’s stock, valued at approximately $91,221,235.52. The disclosure for this sale can be found here. Insiders have sold 125,248 shares of company stock valued at $22,281,673 over the last 90 days. 1.60% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of ILMN. Advocacy Wealth Management Services LLC purchased a new position in shares of Illumina during the first quarter worth $102,000. Gemmer Asset Management LLC increased its position in shares of Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock worth $117,000 after buying an additional 37 shares during the period. Advisory Services Network LLC purchased a new position in shares of Illumina during the first quarter worth $117,000. Patten Group Inc. increased its position in shares of Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after buying an additional 25 shares during the period. Finally, NN Investment Partners Holdings N.V. increased its position in shares of Illumina by 11.3% in the second quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock worth $171,000 after buying an additional 100 shares during the period. Institutional investors and hedge funds own 93.68% of the company’s stock.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.